Medication info

Rometel Tablet 40/20 mg (Telmisartan, Rosuvastatin Calcium)

Prescription medicationTabletOralExpired
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
KOLON Pharmaceuticals Co., Ltd.
Appearance
White oval film-coated tablets
Packaging
30 tablets/box [10 tablets/PTP*3]
Approval status
Expired

MFDS item code 202005527 · Approved 2020.07.29

This product's status changed to Expired on 2025.10.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and reduction of cardiovascular risk and inhibition of atherosclerosis progression
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan and rosuvastatin components. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; for some patients, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with a thiazide diuretic such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after treatment initiation. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medicine orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is not known. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive medication may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased up to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Ingredients

Manufacturer
KOLON Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and reduction of cardiovascular risk and inhibition of atherosclerosis progression

  • Essential hypertension
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • stroke
  • myocardial infarction
View approved original text

This medication is used for patients requiring both Telmisartan and Rosuvastatin. Telmisartan helps reduce the risk of myocardial infarction, stroke, and cardiovascular death in patients with essential hypertension, especially those at high risk of cardiovascular disease. On the other hand, Rosuvastatin is used to improve dyslipidemia such as hypercholesterolemia, slow the progression of atherosclerosis, and also effectively reduce the risk of cardiovascular disease. The combination of these two drugs helps to control blood pressure and blood lipids simultaneously, effectively managing cardiovascular health.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan and rosuvastatin components. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; for some patients, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with a thiazide diuretic such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after treatment initiation. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medicine orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is not known. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive medication may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased up to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Precautions

This medication can cause severe harm or death to a fetus or newborn if used during pregnancy; therefore, it must be discontinued immediately if pregnancy is confirmed. People allergic to this medication or its components, pregnant or potentially pregnant women, nursing mothers, and women of childbearing age who are not using adequate contraception should not use this medication. Patients with severe liver or kidney impairment, certain liver diseases, muscle diseases, and those taking certain other medications should avoid or use this medication with caution. Particular caution is advised for the elderly, patients with hyperkalemia, liver dysfunction, and cardiovascular disease; regular liver function tests and muscle-related evaluations should be conducted. This medication can cause serious muscle-related adverse effects such as myalgia, myopathy, and, rarely, rhabdomyolysis; if symptoms such as muscle pain or weakness occur, immediate consultation with a healthcare provider is necessary. Additionally, it may lead to excessively low blood pressure, and if symptoms of hypotension occur, appropriate measures should be taken. It is important to regularly monitor serum potassium levels and kidney function. This medication can interact with other drugs; therefore, be sure to inform your healthcare provider about all medications currently being taken, especially if using specific diuretics, potassium supplements, anticoagulants, or immunosuppressants. It is safe not to use this medication during pregnancy or while nursing, and women planning to become pregnant should use appropriate contraception. Safety and efficacy in children have not been established, so it is not recommended for pediatric use. In cases of overdose, symptoms such as hypotension, dizziness, and acute renal failure may occur, necessitating immediate medical treatment, as there is no specific antidote and appropriate symptomatic treatment is required. While taking this medication, caution should be exercised as drowsiness or dizziness may occur while driving or operating machinery. Finally, this medication should be kept out of reach of children, and transferring it to other containers should be avoided as it may lead to deterioration of quality and cause accidents.

Side effects

Headache, orthostatic dizziness, sleep paralysis, elevated blood pressure, decreased blood pressure, hypotension, elevated ALT, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, pharyngitis, sinusitis, urinary tract infection, cystitis, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, orthostatic hypotension, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal bloating, vomiting, abdominal discomfort, dry mouth, liver dysfunction, liver injury, increased sweating, itching, rash, erythema, vascular edema, drug rash, toxic skin rash, eczema, urticaria, myalgia, back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated liver enzymes, increased serum CK, decreased hemoglobin, hypoglycemia, vascular edema, hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction syndrome with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, sexual dysfunction, gynecomastia, fatal and nonfatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, headache, dizziness, cough, palpitations, fatigue, nausea, lack of efficacy, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, edema, decreased libido, facial swelling, alopecia, conjunctivitis, tinnitus, petechiae, thrombocytopenia, arthralgia, numbness, discomfort in the chest, abdominal bloating, syncope, generalized pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture; therefore, it must be stored in a tightly closed container. It is important to maintain a storage temperature between 1°C and 30°C room temperature to preserve the effectiveness and safety of the medication.

Appearance and packaging

Appearance

White oval film-coated tablets

Package unit

30 tablets/box [10 tablets/PTP*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.